NCT07546019

Brief Summary

This study evaluates Heuron CTA, a software that helps doctors detect blockages in brain blood vessels using CT angiography images. The software's results will be compared with diagnoses made by medical specialists to assess its accuracy. If it performs well, it may help doctors diagnose these conditions more quickly and effectively.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
270

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 28, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 21, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 21, 2024

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 15, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 22, 2026

Completed
Last Updated

April 22, 2026

Status Verified

April 1, 2026

Enrollment Period

8 months

First QC Date

April 15, 2026

Last Update Submit

April 15, 2026

Conditions

Keywords

Heuron

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity of Heuron CTA in determining the presence of suspected large vessel occlusion

    Sensitivity and specificity of Heuron CTA in determining the presence of suspected large vessel occlusion were assessed by calculating their 95% confidence intervals (CIs) and determining whether the lower bound exceeded the clinical success criterion of 80%. The Clopper-Pearson confidence interval method12) was used to calculate the 95% CI.

    Within 8 weeks after collecting data

Secondary Outcomes (3)

  • Accuracy, ROC Curve and AUC value for classifying suspected large vessel occlusion

    Within 8 weeks after collecting data

  • Sensitivity of Heuron CTA in determining suspected large vessel occlusion for each occluded vessel

    Within 8 weeks after collecting data

  • Sensitivity and specificity of Heuron CTA in determining suspected large vessel occlusion based on adjusted occlusion criteria

    Within 8 weeks after collecting data

Study Arms (2)

Positive Group

Diagnosed with large vessel occlusion due to occlusion of the vessels between ICA and MCA-M1 after taking brain CTA images

Device: Heuron CTA

Negative group

Diagnosed as either not having large vessel occlusion or as normal after brain CTA images

Device: Heuron CTA

Interventions

This software automatically analyzes Computed Tomography Angiography (CTA) images to detect suspected large vessel occlusion, assisting surgeons in their diagnostic decisions

Negative groupPositive Group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

(1) Adults over 19 years old (2) Brain CTA images acquired (3) who confirmed with large vessel occlusion(positive group) or not large vessel occlusion or normal(negative group)

You may qualify if:

  • Adults aged 19 years or older who visited the clinical trial institution for brain CTA images between January 2020 and May 2021, and from November 2021 until IRB approval
  • Individuals classified into the positive or negative group based on the following criteria:
  • Positive group: Diagnosed with large vessel occlusion due to occlusion of the vessels between ICA and MCA-M1 after taking brain CTA images -- Negative group: Diagnosed as either not having large vessel occlusion or as normal after brain CTA images

You may not qualify if:

  • Cases with poor-quality or incomplete brain CTA images7)
  • Cases where intracranial prosthetic implants (e.g., catheters, coils) were present
  • Cases that were previously used for AI model training and internal validation
  • Any other cases deemed unsuitable for participation in the clinical trial based on the investigator's judgment \* Specific reasons were recorded in the case report form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gachon University Gil Medical Center

Incheon, Namdong-gu, 21565, South Korea

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2026

First Posted

April 22, 2026

Study Start

February 28, 2024

Primary Completion

October 21, 2024

Study Completion

October 21, 2024

Last Updated

April 22, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations